Is clinical radiosensitivity a complex genetically controlled event?

Tumori

Volumn 92, Issue 2, 2006, Pages 87-91

  Filippi, Andrea Riccardo ^a,b   Franco, Pierfrancesco ^a   Ricardi, Umberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

DNA repair; Polymorphism; Radiosensitivity

Indexed keywords

ATM PROTEIN; DNA; RAD54 PROTEIN;

ALLELE; ATAXIA TELANGIECTASIA; BLOOM SYNDROME; BREAST CANCER; CHROMOSOME TRANSLOCATION; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; EXPERIMENTAL THERAPY; FANCONI ANEMIA; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; HUMAN; NIJMEGEN BREAKAGE SYNDROME; PHENOTYPE; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE REACTION; GENETICS; NEOPLASM; RADIATION DOSE;

ALLELES; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION TOLERANCE;

EID: 33744764856     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200201     Document Type: Review

References (53)

1. Alter BP: Radiosensitivity in Fanconi's anemia patients. Radiother Oncol, 62: 345-347, 2002.
2. Rogers PB, Plowman PN, Harris SJ, Arlett CF: Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol, 57: 143-154, 2000.
3. Gatti RA: The inherited basis of human radiosensitivity. Acta Oncol, 40: 702-711, 2001.
4. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B, Kysela B, Beamish H, Plowman PN, Arlett CF, Lehmann AR, Jackson SP, Jeggo PA: Identification of a defect in DNA ligase IV in a radiosensitive leukemia patient. Curr Biol, 9: 699-702, 1999.
5. Severin DM, Leong T, Cassidy B, Elsaleh H, Peters L, Venter D, Southey M, McKay M: Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys, 50: 1323-1331, 2001.
6. Ferret M, Hall J: Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair, 3: 1237-1243, 2004.
7. Andreassen CN, Alsner J, Overgaard J: Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it? Radiother Oncol, 64: 131-140, 2002.
8. Barber JB, Burrill W, Spreadborough AR, Levine E, Warren C, Kiltne AE, Roberts SA, Scott D: Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiother Oncol, 55: 179-186, 2000.
9. Budach W, Classen J, Belka C, Bamberg M: Clinical impact of predictive assays for acute and late radiation morbidity. Strahlenther Onkol, 174: 20-24, 1998.
10. Burrill W, Barber JB, Roberts SA, Bulman B, Scott D: Heritability of chromosomal radiosensitivity in breast cancer patients: a pilot study with the lymphocytes micronucleus assay. Int J Radiat Biol, 76: 1617-1619, 2000.
11. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D: Heritability of cellular radiosensitivity: a marker of low penetrance predisposition genes in breast cancer? Am J Hum Genet, 65: 784-794, 1999.
12. Dikomey E, Borgmann J, Peacock J, Jung H: Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys, 56: 1192-1200, 2003.
13. Twardella D, Chang-Claude J: Studies on radiosensitivity from an epidemiological point of view - overview of methods and results. Radiother Oncol, 62: 249-260, 2002.
14. Mariano Ruiz de Almodovar J, Guirado D, Isabel Nunez M, Lopez E, Guerriero R, Teresa Valenzuela M, Villalobos M, del Moral R: Individualization of radiotherapy in breast cancer patients: possible usefulness of a DNA damage assay to measure normal cell radiosensitivity. Radiother Oncol, 62: 327-333, 2002.
15. Tell R, Edgren MR, Sverrisdottir A, Castro J, Fornander T, Hansson LO, Skog S, Lewensohn R: Radiation induced cell cycle response in lymphocytes is not related to clinical side effects in breast cancer patients. Anticancer Res, 23: 3077-3083, 2003.
16. Meyn MS: Ataxia Teleangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet, 55: 289-304, 1999.
17. Weissberg JB, Huang DD, Swift M: Radiosensitivity of normal tissues in ataxia telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys, 42: 1133-1136, 1998.
18. Appleby JM, Barber JB, Levine E: Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer, 76: 1546-1549, 1997.
19. Clarke RA, Gooze GR, Birrell G, Fang ZM, Hasnain H, Lavin M, Kearsley JK: Absence of ATM truncations in patients with severe acute radiation reactions. Int J Radiat Oncol Biol Phys, 41: 1021-1027, 1998.
20. Oppitz U, Bernthaler U, Schindler D: Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late effects. Int J Radiat Oncol Biol Phys, 44: 981-988, 1999.
21. Ramsay J, Birrell G, Lavin M: Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother Oncol, 47: 125-128, 1998.
22. Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahaman N, Ashton A, Moohan M, Wooster R, Owen R, Bliss JM, Stratton MR, Yarnold J: Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer, 78: 922-927, 1998.
23. Iannuzzi CM, Atencio DP, Green S: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys, 52: 606-613, 2002.
24. Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gerard JP, Hall J: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res, 63: 8717-8725, 2003.
25. Bucholtz TA, Wu X, Hussain A, Tucker SL, Mills GB, Haffty B, Bergh S, Story M, Geara FB, Brock WA: Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer, 97: 557-561, 2002.
26. Xia F, Powell SN: The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol, 12: 296-304, 2002.
27. Hofmann W, Schlag PM: BRCA1-BRCA2 breast cancer susceptibility genes. J Cancer Res Clin Oncol, 126: 487-496, 2000.
28. Leong T, Whitty J, Keilar M, Mifurd S, Ramsay J, Birrel G, Venter D, Southey M, McKay M: Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int J Radiat Oncol Biol Phys, 48: 959-965, 2000.
29. Marcou Y, D'Andrea A, Jeggo PA, Plowman PN: Normal cellular radiosensitivity in an adult Fanconi's anemia patient with marked clinical radiosensitivity. Radiother Oncol, 60: 75-79, 2001.
30. Price EA, Bourne SL, Radbourne R, Lawton PA, Lomerdin J, Thompson LH, Arrand JE: Rare microsatellite polymorphism in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet, 23: 237-247, 1997.
31. Thompson LH, West MG: XRCC1 keeps DNA from getting stranded. Mutat Res, 459: 1-18, 2000.
32. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J: Polymorphisms in the DNA repair gene XRCC1, breast cancer risk and response to radiotherapy. Cancer Epidemiol Biomarkers Prev, 12: 1168-1174, 2003.
33. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X: From genotype to phenotype: correlating XRCC1 polymorphism with mutagen sensitivity. DNA Repair, 2: 901-908, 2003.
34. Andreassen CN, Alsner J, Overgaard M, Overgaard J: Prediction of normal tissue radiosensitivity from polymorphism in candidate genes. Radiother Oncol, 69: 127-135, 2003.
35. Quarnby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart AL, Magee B, Kumar S: Association of transforming growth factor beta-1 single nucleotide polymorphism with radiation-induced damage to normal tissue in breast cancer patients. Int J Radiat Biol, 79: 137-143, 2003.
36. Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S: TGF-beta 1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer, 84: 155-159, 1999.
37. Green H, Ross G, Peacock J, Owen R, Yarnold J, Houlston R: Variation in the manganese superoxyde dismutase gene SOD2 is not a major cause of radiotherapy complications in breast cancer. Radiother Oncol, 63: 213-216, 2002.
38. Begg AC, Vens C: Genetic manipulation of radiosensitivity. Int J Radiat Oncol Biol Phys, 49: 367-371, 2001.
39. De Murcia G, Menissier DM: Poly (ADPribose) polymerase: a molecular nick-sensor. Trend Biochem Sci, 19: 172-176, 1994.
40. Jeggo PA: DNA repair: PARP - another guardian angel? Curr Biol, 8: 49-51, 1998.
41. Rudat V, Kupper JH, Weber KJ: Trans-dominant inhibition of poly (ADP-ribosylation) leads to decreased recovery from ionizing radiation cell killing. Int J Radiat Oncol Biol Phys, 73: 325-330, 1998.
42. Bristow RG, Jang A, Peacock J, Chung S, Benchimol S, Hill RP: Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-Eqn 7 and/or activates H-ras. Oncogene, 9: 1527-1536, 1994.
43. Yang YM, Dolan LR, Ronai Z: Expression of dominant CREB reduces resistance to radiation of human melanoma cells. Oncogene, 12: 2223-2233, 1996.
44. Hallahan DE, Dunphy E, Viriduchalam, Sukhatme VP, Kufe DW, Weichselbaum RR: C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. J Biol Chem, 270: 30303-30309, 1995.
45. Uhrammer N, Fritz E, Boyden, C, Meyn MS: Human fibroblasts transfected with an antisense vector respond abnormally to ionizing radiation. Int J Mol Med, 4: 43-47, 1999.
46. Zhang N, Chen P, Gatei M, Scott S, Khanna K, Lavin MF: An antisense construct of full-length ATM cDNA imposes a radiosensitivity phenotype on normal cells. Oncogene, 17: 811-818, 1998.
47. Essers J, Hendricks RW, Swagemakers SM, Troelstra C, de Wit J, Bootsma D, Hoeijmakers JH, Kanaar R: Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell, 89: 195-204, 1997.
48. Ohnishi T, Taki T, Hiraga S, Arita N, Monta T: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the rad51 gene. Biochem Biophys Res Commun, 245: 319-324, 1998.
49. Johnson GC, Todd JA: Strategies in complex disease mapping. Curr Opin Genet Dev, 10: 330-334, 2000.
50. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol, 23: 1826-1832, 2005.
51. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y: Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia, 4: 295-303, 2004.
52. Park WY, Hwang CI, Im CN, Kang MJ, Woo JH, Kim JH, Kim YS, Kim JH, Kim H, Kim KA, Yu HJ, Lee SJ, Lee YS, Seo JS: Identification of radiation-specific responses from gene expression profile. Oncogene, 21: 8521-8528, 2002.
53. Rieger KE, Hong WJ, Tusher VG, Tang J, Tibshirami R, Chu G: Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proc Natl Acad Sci, 17: 6635-6640, 2004.